- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 29.08. | Thor Medical To Supply Thorium-228 For Oncoinvent's Phase 3 Radspherin Program | 2 | RTTNews | ||
| 29.08. | Thor Medical ASA: Thor Medical and Oncoinvent Enter Strategic Thorium-228 Supply Agreement | 2 | Oslo Børs | ||
| 29.08. | ONCOINVENT AS: Thor Medical and Oncoinvent Enter Strategic Thorium-228 Supply Agreement | 4 | Cision News | ||
| 27.08. | Oncoinvent im Q2 2025: Umsatzsprung und erfolgreiche Kostensenkungen | - | Investing.com Deutsch | ||
| 27.08. | Oncoinvent advances phase 2 ovarian cancer trial, reports positive data | 3 | Investing.com | ||
| 27.08. | Oncoinvent: Starke Studiendaten und verbesserte Finanzlage ebnen Weg für Fusion | 2 | Investing.com Deutsch | ||
| ONCOINVENT Aktie jetzt für 0€ handeln | |||||
| 27.08. | Oncoinvent H1 2025 slides reveal strong clinical data and improved financials | 2 | Investing.com | ||
| 27.08. | Oncoinvent ASA half-yearly report: Strong focus on financial discipline and advancing Phase 2 program in ovarian cancer | 289 | PR Newswire | OSLO, Norway, Aug. 27, 2025 /PRNewswire/ -- Oncoinvent reports continued progress in the ongoing Phase 2 trial in ovarian cancer with a strong focus on advancing the program and maximizing... ► Artikel lesen | |
| 22.08. | Oncoinvent ASA invites to a webcast presentation of 1H 2025 on Wednesday 27 August 2025 | 1 | Oslo Børs | ||
| 04.08. | Oncoinvent ASA: Oncoinvent shareholders approve the merger plan with BerGenBio | - | Oslo Børs | ||
| 03.07. | Oncoinvent ASA: Notice of Extraordinary General Meeting | - | Oslo Børs | ||
| 01.07. | BerGenBio, in wake of lead cancer drug's failure, opts to merge with radiopharma Oncoinvent | 1 | FierceBiotech | ||
| 30.06. | Oncoinvent AS: Announcement of fully underwritten rights issue | 554 | PR Newswire | OSLO, Norway, June 30, 2025 /PRNewswire/ -- BerGenBio ASA the ("Company") hereby announces a fully underwritten rights issue with preferential subscription rights (the "Subscription Rights")... ► Artikel lesen | |
| 30.06. | Oncoinvent AS: BerGenBio and Oncoinvent, a rising innovator in radiopharmaceutical cancer therapies, announce proposed merger and a fully underwritten rights issue | 303 | PR Newswire | OSLO, Norway, June 30, 2025 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO) ("BerGenBio" or the "Company") and Oncoinvent ASA (OSE: ONCIN) ("Oncoinvent") announce that they have entered into a... ► Artikel lesen | |
| 18.06. | Oncoinvent ASA: Oncoinvent: Invitation to Presentation of Positive Final Data from Phase 1/2a Trial of Radspherin® in Patients with Colorectal Peritoneal Metastases | 1 | Oslo Børs | ||
| 18.06. | Oncoinvent AS: Oncoinvent Announces Positive Final Data from Phase 1/2a Trial of Radspherin in Patients with Colorectal Peritoneal Metastases | 287 | PR Newswire | Data demonstrate sustained peritoneal disease control and reinforce the potential of Oncoinvent's novel radiopharmaceutical therapy to target peritoneal disease in colorectal cancer
OSLO... ► Artikel lesen | |
| 18.06. | Oncoinvent ASA: Oncoinvent Announces Positive Final Data from Phase 1/2a Trial of Radspherin® in Patients with Colorectal Peritoneal Metastases | 2 | Oslo Børs | ||
| 14.05. | Oncoinvent ASA: Minutes from the annual general meeting 2025 | - | Oslo Børs | ||
| 30.04. | Oncoinvent Q1 2025 slides: promising cancer therapy data, solid cash position | 1 | Investing.com | ||
| 30.04. | Oncoinvent ASA: Notice of Annual General Meeting | - | Oslo Børs |
1 2 Weiter >>
34 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 96,35 | +8,32 % | BioNTech erreicht Phase-3-Erfolg bei Brustkrebsstudie mit BNT323 | BioNTech hat gemeinsam mit DualityBio einen wichtigen Studienerfolg erzielt: In einer von DualityBio in China durchgeführten Phase-3-Studie erreichte der Antikörper-Wirkstoff-Kandidat Trastuzumab Pamirtecan... ► Artikel lesen | |
| QIAGEN | 40,390 | +0,44 % | dpa-AFX-Überblick: UNTERNEHMEN vom 29.08.2025 - 15.15 Uhr | ROUNDUP: Gerresheimer bekommt überraschend neuen Finanzchef - Aktie erholt DÜSSELDORF - Der zuletzt schwächelnde Pharmaverpackungshersteller Gerresheimer bekommt überraschend einen neuen Finanzchef.... ► Artikel lesen | |
| EVOTEC | 5,856 | +2,70 % | Evotec Aktie: Bringt der "Insiderkauf" die große Kurs-Wende? | Ein großer "Insiderkauf" machte bei der Evotec Aktie in dieser Woche Schlagzeilen. Wer dachte, dass der Aktienkauf des CEO von Evotec im Wert von knapp 0,3 Millionen Euro aber massive Dynamik in die... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 51,29 | +5,69 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights | Aligned with FDA on del-brax accelerated and full approval pathways for FSHD, reported positive topline data from Phase 1/2 FORTITUDE trial, and initiated global... ► Artikel lesen | |
| FORTRESS BIOTECH | 3,295 | +15,82 % | Fortress Biotech, Inc.: Fortress Biotech Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights | Fortress subsidiary Checkpoint Therapeutics acquired by Sun Pharma; Fortress received ~$28 million at closing and is eligible to receive up to an additional $4.8 million under a contingent value right... ► Artikel lesen | |
| BEAM THERAPEUTICS | 20,190 | +8,78 % | Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease | CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that... ► Artikel lesen | |
| Y-MABS THERAPEUTICS | 8,580 | +0,12 % | Y-mAbs Therapeutics, Inc.: Y-mAbs Reports Second Quarter 2025 Financial Results and Recent Corporate Developments | Reported Total Revenues of $19.5 million for the second quarter of 2025, exceeding the high end of the Company's guidance range of between $17 million and $19 millionSERB Pharmaceuticals to acquire... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 45,400 | 0,00 % | 1 Reason Every Investor Should Know About CRISPR Therapeutics (CRSP) | ||
| SUMMIT THERAPEUTICS | 25,830 | +8,51 % | Summit Therapeutics stock maintains Buy rating at H.C. Wainwright on ivonescimab progress | ||
| RECURSION PHARMACEUTICALS | 4,615 | +2,21 % | If You'd Invested $1,000 in Recursion Pharmaceuticals 4 Years Ago, Here's How Much You'd Have Today | ||
| BIOARCTIC | 27,060 | -6,30 % | BioArctic: FDA gibt grünes Licht für Alzheimer-Medikament in neuer Darreichungsform | Die Aktien des schwedischen Biotech-Unternehmens BioArctic legten am Montag um mehr als zwei Prozent zu. Hintergrund ist die Zulassung einer neuen Version des Alzheimer-Mittels Leqembi durch die US-Arzneimittelbehörde... ► Artikel lesen | |
| ARS PHARMACEUTICALS | 10,375 | -2,86 % | Roth/MKM initiates ARS Pharmaceuticals stock with Buy rating on neffy potential | ||
| BB BIOTECH | 36,400 | +0,41 % | EQS-PVR: BB BIOTECH AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution | EQS Voting Rights Announcement: BB BIOTECH AG
BB BIOTECH AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide... ► Artikel lesen | |
| NUVATION BIO | 4,045 | +18,45 % | Nuvation Bio To Present New Data on IBTROZI (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual Congresses | Presentations to include updated and additional Phase 2 clinical data for recently FDA-approved IBTROZI
Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the... ► Artikel lesen | |
| COGENT BIOSCIENCES | 13,100 | +1,16 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Positive Top-line Results Achieving Statistical Significance Across All Primary and Key Secondary Endpoints from the SUMMIT Trial of Bezuclastinib in Patients with Non-Advanced ... | -- Patients treated with bezuclastinib showed a superior mean change in total symptom score at 24 weeks (-24.3 points vs. -15.4 points, -8.91 point placebo-adjusted difference; p=0.0002), compared... ► Artikel lesen |
ONCOINVENT ASA gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -0,52 % bei einem Aktienkurs von 0,115 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ONCOINVENT ASA finden Sie auf Wallstreet Online.